Valuation: Geron Corporation

Market Cap 821M 721M 664M 618M 1.17B 78.07B 1.19B 7.98B 3.09B 38.32B 3.08B 3.02B 133B P/E 2026 *
-64x
P/E 2027 * 19.7x
Enterprise Value 800M 703M 647M 603M 1.14B 76.08B 1.16B 7.78B 3.01B 37.34B 3B 2.94B 130B EV / Sales 2026 *
3.42x
EV / Sales 2027 * 1.96x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week-7.94%
Current month-0.39%
1 month+5.37%
3 months-23.19%
6 months-3.41%
Current year-3.41%
1 week 1.26
Extreme 1.26
1.47
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-7.94%-7.61%-59.91% 821M
-2.19%+6.01%+66.90%+127.13% 57.65B
+0.55%+17.77%+80.01%+100.93% 55.14B
+0.07%+2.97%-13.60%-13.85% 23.53B
+0.57%+3.37%+9.55%+415.40% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+0.28%+5.51%+36.93%-30.58% 16.84B
-1.11%+1.55%+23.09%+180.66% 13.68B
+0.14%+9.60%+33.31% - 12.97B
-1.27%+3.18%+75.22%+132.95% 12.38B
Average -0.53%+4.70%+33.87%+93.87% 23.43B
Weighted average by Cap. -0.60%+4.59%+47.37%+115.59%

Financials

2026 *2027 *
Net sales 234M 205M 189M 176M 332M 22.22B 339M 2.27B 880M 10.91B 878M 859M 37.96B 333M 292M 269M 251M 473M 31.67B 483M 3.24B 1.25B 15.55B 1.25B 1.22B 54.11B
Net income -13.95M -12.25M -11.28M -10.51M -19.82M -1.33B -20.22M -136M -52.55M -651M -52.39M -51.26M -2.27B 46.55M 40.87M 37.62M 35.05M 66.11M 4.43B 67.45M 452M 175M 2.17B 175M 171M 7.56B
Net Debt -20.97M -18.41M -16.95M -15.79M -29.78M -1.99B -30.39M -204M -78.97M -979M -78.73M -77.03M -3.41B -169M -148M -137M -127M -240M -16.07B -245M -1.64B -636M -7.89B -635M -621M -27.45B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
02/07/26 USD 1.275 -0.39% 5,701,296
30/06/26 USD 1.280 -1.54% 12,592,432
29/06/26 USD 1.300 -1.52% 14,561,547
26/06/26 USD 1.320 -3.65% 36,634,117
25/06/26 USD 1.370 -1.08% 9,546,037
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.280USD
Average target price
3.400USD
Spread / Average Target
+165.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock